Astellas Pharma (TYO:4503) said preliminary US sales of Izervay or avacincaptad pegol reached 15.9 billion yen or $110 million in the fiscal first quarter, according to its Tokyo bourse filing on Thursday.
The sales figures for the three months ended June were shared during an investment community meeting held on the same day.
Astellas will provide a detailed breakdown of its fical Q1 financial results, including Izervay performance, during its earnings call scheduled for July 30.
The drug treats geographic atrophy (GA), a severe form of age-related macular degeneration (AMD).
Shares of the pharma company declined over 1% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.